Servier’s VORANIGO (vorasidenib) Tablets Receives FDA Approval as First Targeted Therapy for Grade 2 IDH-mutant Glioma Read more
Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases Read more
SK pharmteco and Rznomics Explore Collaboration for RNA-based Gene Therapy Development and Manufacturing Read more
Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care Read more
Boehringer Ingelheim secures novel immune checkpoint inhibitor with acquisition of Nerio Therapeutics Read more
Novartis Scemblix granted FDA Priority Review for the treatment of adults with newly diagnosed CML Read more
Sandoz launches biosimilar Pyzchiva (ustekinumab) across Europe, to treat chronic inflammatory diseases Read more
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease Read more
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor Read more